BioNTech SE

BNTX

Equity

ISIN US09075V1026 / Valor 50030055

NASDAQ (2024-11-22)

USD 113.13+4.53%

BioNTech SE
UMushroom community rating:

4.00 1 votes No rating yet

NegativeNeutralPositive

About company

BioNTech SE is a biotechnology company focused on improving global health through the research and development of immunotherapies. Founded by scientists and physicians, the company is dedicated to translating scientific advancements into life-saving treatments by leveraging a diverse toolbox of drug classes and platform technologies, including mRNA-based therapies, cell therapies, small molecules, antibodies, and other protein-based therapies. BioNTech's innovative approach aims to provide personalized and effective treatments for patients worldwide, with a particular focus on developing novel cell therapies for targeting cancer-specific antigens, such as chimeric antigen receptor (CAR) T cell therapies and T cell receptor (TCR) programs. Additionally, the company is exploring the combination of mRNA FixVac platform with CAR T product candidates to enhance the persistence of CAR-T cells in vivo.

Summarized from source with an LLMView SourceSector: Technology

Revenue Decline

BioNTech SE reported revenues of €128.7 million for the second quarter of 2024, a decrease from €167.7 million in the same quarter of the previous year. This decline is primarily attributed to lower sales of COVID-19 vaccines as the market shifts from pandemic to seasonal endemic demand.

Net Loss

For the second quarter of 2024, BioNTech SE experienced a net loss of €807.8 million, significantly higher than the €190.4 million loss reported in the same period of 2023. This increase in net loss is largely due to higher research and development expenses and other operating costs.

Research and Development Expenses

BioNTech SE's research and development expenses for the second quarter of 2024 were €584.6 million, up from €373.4 million in the same quarter of the previous year. The increase is mainly driven by the progression of clinical studies for late-stage oncology pipeline candidates and higher personnel costs.

Cash Position

As of June 30, 2024, BioNTech SE had cash, cash equivalents, and security investments totaling €18.5 billion. This strong cash position was bolstered by a significant payment from collaboration partner Pfizer Inc.

Full-Year Revenue Guidance

BioNTech SE has reiterated its full-year 2024 revenue guidance, expecting total revenues to be in the range of €2.5 billion to €3.1 billion. This outlook considers various factors, including regulatory approvals, COVID-19 vaccine uptake, and seasonal variations in demand.

Summarized from source with an LLMView Source

Key figures

15.5%1Y

-64.8%3Y

430%5Y

Performance

39.0%1Y

52.9%3Y

79.1%5Y

Volatility